• The Journal of Internal Korean Medicine
• /
• v.26 no.1
• /
• pp.119-128
• /
• 2005

모든 알레르기 반응의 중심축이 되는 비만세포는 주로 피부, 위장관 및 호흡기관의 점막에 분포하고 있다. 활성화된 비만세포는 즉각형 알레르기 반응을 일으키는 여러 인자들을 방출시키게 된다. 方藥合編(방약합편)에 따르면 蔘蘇飮(삼소음)은 알레르기 鼻炎(비염), 發熱(발열), 風寒(풍한), 頭痛(두통), 기침에 效能(효능)이 있는 處方(처방)이다. 본 硏究(연구)는 蔘蘇飮(삼소음)의 肥滿細胞(비만세포) 의존성 아나필락시 반응(anaphylactic reaction)에 대한 藥理(약리) 效果(효과)를 조사하기 위한 것이다. 蔘蘇飮(삼소음)은 compound 48/80으로 유발되는 전신성 아나필락시 쇼크(systemic anaphylactic shock)와 耳介(이개) 浮腫(부종) 反應(반응)(ear swelling response)을 농도 의존적으로 억제하였다. 蔘蘇飮(삼소음)을 0.1, 1 mg/ml로 전처리 하였을 때, 흰쥐 복강 肥滿細胞(비만세포)(rat peritoneal mast cells, RPMCs)에서 compound 40/80에 의해 유발되는 히스타민 분비는 감소하는 것으로 나타났다. 또한 蔘蘇飮(삼소음)은 anti-dinitrophenyl IgE에 의해 활성화 된 수동 피부 아나필락시(passive cutaneous anaphylaxis, PCA)를 농도 의존적으로 抑制(억제)하였다. 결론적으로 蔘蘇飮(삼소음)은 肥滿細胞(비만세포) 의존성 즉각형 알레르기 反應(반응)을 抑制(억제)하여, 항 아나필락시 활성(anti-anaphylactic activity)을 가지는 것으로 보여 진다.

• Biomolecules & Therapeutics
• /
• v.1 no.2
• /
• pp.236-243
• /
• 1993

Immunologic potential of DA-125, a new anthracycline antitumor antibiotic, was investigated using guinea pigs and mice. In antigenicity experiments, guinea pigs were sensitized subcutaneously with DA-125 or DA-125 incorporated in complete Freund's adjuvant (CFA) once a week for three weeks. No systemic anaphylaxis was induced by intravenous injection of DA-125 or DA-125 incubated with guinea pig serum after 3 weeks from the last sensitization. None of sera of these animals showed any passive cutaneous anaphylactic reaction (PCA) when DA-125 or DA-125 incubated with guinea pig serum was used as a challenging antigen in homologous PCA experiment. On the other hand the treatment of guinea pigs with ovalbumin Incorporated in CFA induced systemic anaphylactic reaction when challenged by intravenous injection of 5 mg/body of ovalbumin. Immunodiffusion test revealed no precipitating antibodies as detected in guinea pigs sensitized with DA-125. In 24-hour heterologous PCA reaction with sera of C57BL/6 mice immunized with DA-125 or DA-125 mixed with aluminum hydroxide gel (Alum), None of sera showed positive reaction when DA-125 or DA-125 incubated with rat serum was used as a challenging antigen. Sera of animals immunized with a mixture of ovalbumin and alum showed positive PCA reaction when 5 mg/body of ovalbumin was injected as a challenging antigen. In lymphocyte proliferation tests, spleen lymphocyte proliferation to PHA and LPS was similarly impaired by 12 mg/kg of DXR or 36 mg/kg of DA-125, and the immunodepressive activity of DA-125 showed a dose-dependent manner. From these results, it could be concluded that immunosupression of DA-125 would be comparable to that of DXR and that DA-125 would not induce systemic allergic reaction in its clinical use.

• Journal of Veterinary Clinics
• /
• v.37 no.3
• /
• pp.145-148
• /
• 2020

A 9-years old spayed female Maltese was referred for the treatment of mass on the right 1^st mammary gland and acute weight bearing lameness of right hindlimb. It was diagnosed as malignant mammary tumor and cranial cruciate ligament rupture of right stifle joint. Right upper regional mastectomy followed by cranial closing wedge osteotomy (CCWO) of the right tibia were planned for the present problems. Preanesthetic work-up did not show any remarkable abnormalities. Forty-five minutes after induction of anesthesia dobutamine was administered at a rate of 5 ㎍/kg/min by constant rate infusion due to gradual decrease of blood pressure below MAP 60 mmHg during surgical procedure. Despite of the increase of dobutamine infusion rate up to 20 ㎍/kg/min, blood pressure didn't recover. At the end of regional mastectomy generalized skin redness and eyelid edema were identified. Anesthesia was stopped and CCWO procedure was cancelled. To recover from the anaphylactic reactions dexamethasone and diphenhydramine were administered. After about one hour, the patient completely recovered from hypotension and anaphylactic reactions. After 4 weeks, intradermal skin test (IDST) was performed for all the drugs used during anesthesia. Only dobutamine showed positive reaction in IDST. Therefore, dobutamine was considered as the causative agent of anaphylaxis in this patient during the anesthesia. In case of perioperative anaphylactic reaction, postoperative investigation should be performed to identify causative agent and to provide safe recommendations for future anesthetic procedure.

• Proceedings of the PSK Conference
• /
• 2000.04a
• /
• pp.193.1-193.1
• /
• 2000

• The Journal of Korean Medicine Ophthalmology and Otolaryngology and Dermatology
• /
• v.12 no.1
• /
• pp.1-17
• /
• 1999

Shinisan has been used for treatment of allergic disease in Oriental Medicine. However, its effect in experimental models remains unknown. The mast cell plays a pivotal role in initiating allergic response by secreting intracytoplasmic granular mediators such as histamine. The present report describes an inhibitory effect of Shinisan on mast cell-mediated immediate type allergic reactions. Topical application of compound 48/80 can induce an ear swelling response in normal ($WBB6F_1-+/+$) mice but not in the congenic mast cell-deficient $WBB6F_1-W/W^v$ mice. Shinisan inhibited concentration-dependently mast cell-dependent ear swelling response induced by compound 48/80. Shinisan inhibited concentration-dependently passive cutaneous anaphylaxis induced by anti-dinitrophenyl (DNP) IgE in rats by topical application. Shinisan also inhibited concentration-dependently the histamine release from the rat peritoneal mast cells by compound 48/80 or anti-DNP IgE. Moreover, Shinisan had a significant inhibitory effect on compound 48/80-induced systemic anaphylactic reaction. These results indicate that Shinisan inhibits immediate-type allergic reactions by inhibition of mast cell degranulation in vivo and in vitro.

• Biomolecules & Therapeutics
• /
• v.4 no.4
• /
• pp.334-338
• /
• 1996

Antigenicity of DA-3285, human recombinant erythropoietin which was produced from mammalian cells, was examined in guinea pigs and mice. In active systemic anaphylactic test, mild anaphylactic signs were observed in guinea pigs sensitized subcutaneously with DA-3285 or DA-3285 incorporated with complete Freund's adjuvant(CFA) when challenged with high dose(1000 IU/Kg) of DA-3285. Other groups showed negative responses. In mouse-rat passive cutaneous anaphylaxis test, 20% sera of mice immunized with DA-3285 or DA-3285 mixed with aluminum hydroxide(alum) showed mild positive responses. In the case of indirect haemagglutination reaction(IHA) test, when sheep red blood cells coated with DA-3285 was incubated with mouse serum, all the serum samples were showed negative responses. These results suggest that DA-3285 has a very weak antigenic potential and probably would not induce systemic allergic reactions in clinical uses.

• The Journal of Internal Korean Medicine
• /
• v.11 no.2
• /
• pp.22-42
• /
• 1990

Sabaiksan has been prescribed to treat various allergic diseases in herbal medicine which were induced by various vasoactive amine released from the mast cells. The constituents of Sabaiksan are Mori Cortex Radices(MCR), Lycii Cortex Radicis(LCR) and Glycyrrhizae Radix(GR). Recently, simple models of compound 48/80 induced anaphylactic shock and cutaneous reaction in vivo were developed to test various agents employed in the field of allergy and toxicology research. The purpose of this study is to evaluate the effects of Sabaiksan on compound 48/80 induced anaphylactic stock, cutaneous reaction and mesenteric mast cell degranulation rate in ICR mice, and on compound 48/80 induced peritoneal mast cell degranulation and histamine release in vitro. Groups of ICR mice were intraperitoneally pretreated with $100{\mu}{\ell}$ of saline, $MCR(2g/m{\ell}),\;LCR(2g/m{\ell}),\;GR(g/m{\ell})$ or Sabaiksan itself(MCR+LCR+GR) at 24, 12 and 1 hour before compound 48/80 solution ($10{\mu}{\ell}/gm$ B. W) were peritoneally given into them, and then mortality within 72 hours after the compound 48/80 injection, and mesenteric mast cell degranulation rate at 15 minutes after compound 48/80 injection were calculated. In vitro experiment, $400{\mu}{\ell}$ of rat peritoneal mast cell suspension$(10^6cell/m{\ell})$ were pretreated with $50{\mu}{\ell}$ of saline, $MCR(2g/m{\ell}),\;LCR(2g/m{\ell}),\;GR(g/m{\ell})$ or Sabaiksan itself at room temperature for 30 minutes, and then $50{\mu}{\ell}$ of compound 48/80 solution $(100{\mu}g/m{\ell})$ were added into it. 30 minutes after the addition of compound 48/80 solution, histamine release assay in the supernatant of peritoneal mast cell suspension were performed employing radioisotope enzymatic assay and morphologic changes of mast cells in each regular time point were photographed. Compared with controls, compound 48/80 induced anaphylactic shock was significantly inhibited by MCR and GR pretreatment into the ICR mice. Significant inhibition of compound 48/80 induced cutaneous reaction, mesenteric mast cell degranulation rate in vivo and histamine release from the rat peritoneal mast cells in vitro was observed only in MCR pretreated group. From the above results, it is suggested that MCR component of Sabaiksan may playa key role to suppress mast cell function since it has been applied to various allergic diseases.

• The Journal of the Korean Society for Microbiology
• /
• v.13 no.1
• /
• pp.17-24
• /
• 1978

Modulating effects of Candida albicans on the immune responses of mice immunized with sheep red blood cells(SRBC) were assessed both by footpad tests for anaphylactic, Arthus and delayed type hypersensitivity rections against homologous and heterologous antigenic challenges and by serum antibody titrations for hemagglutinin and hemolysin against SRBC. The results are summarized as follows: 1. In the mice simultaneously immunzed with C. albicans and SRBC, anaphylactic type and Arthus type footpad reactions to C. albicans challenge were enhanced, and extents of the enhancements were proportional to the concentration of SRBC administered for immunization, reaching peak in mice immunized with 0.2ml($10^8$) of 5% SRBC suspension. Although a little enhancement of delayed type hypersensitivity to C. albicans was observed in those mice, there was no significant difference between the mice groups immunized either with SRBC alone or SRBC and C. albicans simultaneously. 2. Simultaneous immunization of mice with C. albicans and SRBC resulted in the suppression of both anaphylactic type and Arthus type footpad reactions to SRBC, and the extent of such suppressions was inversly proportional to the numbers of C. albicans administered for immunization. Delayed type reaction of the mice to SRBC varied little in regards to the different numbers of C. albicans injected. 3. Hemagglutinin titers differed little between the mice groups immunized with SRBC alone or with SRBC and C. albicans simultaneously. Hewever, hemolysin titers were lower in the mice immunized simultaneously with SRBC and C. albicans. 4. In the peripheral blood of mice immunized simultaneously with SRBC and C. albicnas. there observed increases in the percents of monocyte and polymorphonuclear leukocytes and decrease in the numbers of lymphocytes and pyroninophilic lymphocytes. These results indicated that C. albicans is an immunosuppressant of the mice to SRBC when both anteigns were administered simultaneously for immunization, and that SRBC acted as an enhancer of anaphylactic type and Arthus type reaction of mice to C. albicans when administered simultaneously.

• Natural Product Sciences
• /
• v.7 no.4
• /
• pp.95-101
• /
• 2001

We investigated the effect of aqueous extract of Terminalia chebula (Combretaceae)(TCAE) on the immediate hypersensitivity reaction in vivo and in vivo. TCAE (0.01 to 1 g/kg) dose-dependently inhibited compound 48/80 induced systemic anaphylaxis in mice. When TCAE was pretreated at concentrations ranging from 0.01 to 1 g/kg, the plasma histamine levels were reduced in a dose-dependent manner. TCAE (0.1 and 1 g/kg) significantly inhibited local immunoglobulin E (IgE)-mediated passive cutaneous anaphylactic reaction. TCAE (0.001 to 1 mg/ml) also dose-dependently inhibited the histamine release from rat peritoneal mast cells (RPMC) activated by compound 48/80 or anti-dinitrophenyl (DNP) IgE. TCAE (0.01 to 1 mg/ml) had a significant inhibitory effect on anti-DNP IgE-induced tumor necrosis $factor-{\alpha}$ production from RPMC. These results indicate that TCAE inhibits immediate hypersensitivity reaction in vivo and in vitro.

• The Journal of Korean Medicine Ophthalmology and Otolaryngology and Dermatology
• /
• v.11 no.1
• /
• pp.40-53
• /
• 1998

Mast cells play an important role in the pathophysiologlcal changes observed in acute cutaneous and inflammatory diseases In order to see whether Kum-Hwang-San has an influence on mast cell- mediated immediate cutaneous reactions, the author has undertaken an animal study. Ears of mice were treated with a compound 48/80 solution topically at 30 min after the cutaneous application of Kum-Hwang-San. At each point, an ear swelling response was measured with a digimatic thickness micrometer. Ear swelling response induced by compound 48/80 was significantly suppressed dose-dependently by Kum-Hwang-San 30 min before topical application as compared with that in nonapplicated control mice, and the value returned to normal levels by 120 min. Compound 48/80- induced mast cell degranulation by Kum-Hwang-San was also remarkably decreased in accordance with the suppression in ear swelling response. Kum-Hwang-San dose-dependently inhibited histamine release from the rat peritoneal mast cells activated by compound 48/80. Another way to test acute cutaneous reaction is to induce passive cutaneous anaphylactic reaction. Kum-Hwang-San significantly inhibited passive cutaneous anaphylactic reaction activated by anti-dinitrophenyl IgE on both topical application and intradermal injection. Kum-Hwang-San also inhibited histamine release from the rat peritoneal mast cells induced by anti-DNP IgE. This study provides evidence that Kum-Hwang-San will be beneficial in the treatment of acute cutaneous diseases.